How well Acceptance and Commitment Therapy (ACT), or tailored “talk” therapy that can be delivered via telemedicine, helps people with…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Claire’s Place Foundation is preparing for its 5th Annual Glow Ride event to raise money to support families affected…
The presence of the fungus Aspergillus fumigatus is linked to lower respiratory-related quality of life in people with cystic…
Path BioAnalytics (PBA), a biotechnology company based in North Carolina, has licensed the rights to further develop cavosonstat (N91115), a targeted…
A 10th anniversary screening of the documentary “65_RedRoses” will take place on Sunday, Sept. 8, at the Vancouver Playhouse Theatre…
The first patient has been dosed in a Phase 2 clinical trial testing Proteostasis Therapeutics‘s combinations of three investigational…
Vertex Pharmaceuticals is asking the U.S. Food and Drug Administration to approve a first triple combination therapy — elexacaftor…
Poorer lung function in pregnant women with cystic fibrosis (CF) is associated with a lower birth weight for offspring,…
AzurRx BioPharma has initiated a Phase 2 clinical trial testing its oral capsule MS1819-SD, combined with standard porcine…
Adding cystic-fibrosis-specific variables to the lung allocation score allows for more accurate identification of patients who are likely to benefit…